Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2024-03-28 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于长春百克生物科技股份公司2023年持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is a detailed onsite inspection report by a sponsor (中信证券股份有限公司) regarding the continuous supervision work for 长春百克生物科技股份公司 during 2023. It covers governance, internal controls, information disclosure, independence, related party transactions, fundraising usage, and operational status. The report references regulatory rules and laws related to securities issuance and listing supervision. It is a standalone audit/inspection report focusing on compliance and supervisory findings rather than a full annual or interim financial report. The document length is about 3,077 characters, which is sufficient for a substantive report but not a brief announcement. It is not a certification letter, earnings release, or a presentation. The content aligns with an Audit Report / Information (AR) filing, as it details the results of a regulatory onsite inspection and compliance review by the sponsor, which fits the AR category definition. FY 2023
2024-03-28 Chinese
长春百克生物科技股份公司2023年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2023 年年度股东大会会议资料" which translates to "2023 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda, meeting notices, reports from the board and supervisory committee, voting procedures, and other materials typically distributed for an AGM. The content includes the schedule, meeting rules, reports for shareholder review, and voting instructions, all consistent with materials prepared for an Annual General Meeting. There is no indication that this is the full Annual Report (10-K) or a financial statement filing, but rather the materials provided to shareholders for the AGM. Therefore, the document fits the category of AGM Information (AGM-R). The document length is substantial (15,000 characters), indicating it is the meeting materials themselves, not just an announcement of a report publication.
2024-03-28 Chinese
中信证券股份有限公司关于长春百克生物科技股份公司2023年度持续督导跟踪报告
Regulatory Filings
2024-03-26 Chinese
国泰君安证券股份有限公司关于长春百克生物科技股份公司2022年限制性股票激励计划首次授予部分第一个归属期归属条件成就事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to a 2022 restricted stock incentive plan for Changchun Baike Biotechnology Co., Ltd. It includes detailed explanations of the stock incentive plan, authorization and approval processes, and the achievement of vesting conditions. The document is prepared by Guotai Junan Securities Co., Ltd. as an independent financial advisor. It is not a general annual report, earnings release, or management discussion, but a specialized advisory report on a stock incentive plan. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to equity incentives and capital structure changes involving restricted stock grants and vesting conditions. The document length is substantial (15,000 characters), and it contains detailed substantive content rather than just an announcement or certification. Therefore, the classification is CAP with high confidence.
2024-03-19 Chinese
长春百克生物科技股份公司关于独立董事独立性自查情况的专项报告
Governance Information Classification · 95% confidence The document is a special report on the independence of the company's independent directors, referencing regulatory requirements from the China Securities Regulatory Commission and Shanghai Stock Exchange rules. It is a compliance-related report focusing on governance and director independence, not a financial report or announcement of voting results. The content aligns with governance-related disclosures rather than management changes or remuneration. Therefore, it fits best under Governance Information (CGR). The document length is short but contains substantive content, not just an announcement or certification, so it is not RNS or RPA.
2024-03-19 Chinese
长春百克生物科技股份公司第五届董事会第二十三次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 23rd meeting of the 5th Board of Directors of Changchun Baike Biotechnology Co., Ltd. It includes multiple agenda items such as approval of the 2023 Board Work Report, 2023 Financial Statements, Profit Distribution Plan, 2023 Annual Report, ESG Report, and other reports. The document states that these items are to be submitted to the shareholders' meeting for approval and references that the full reports are disclosed separately on the Shanghai Stock Exchange website. The document is not the actual annual report or financial statements but a formal announcement of board meeting decisions and approvals. It is a typical Board/Management Information announcement about board resolutions and management decisions. The document length is under 5,000 characters and does not contain the full reports themselves, so it is not the Annual Report (10-K) or Interim Report (IR). It is not a report publication announcement since it contains substantive board meeting resolution details. Therefore, the correct classification is Board/Management Information (MANG).
2024-03-19 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.